Quo
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RSLS >>> Shares Outstanding: 23,457,090
Insider Shares: 17,566,310
Insider Ownership: 74.89%(!)
Total Insiders: 76(!)
Link: https://fintel.io/sn/us/rsls
$$$RSLS$$$
Rather sooner than later... ;)
You're welcome, buddy.
$RSLS >>> ReShape Lifesciences Inc. (RSLS) Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device
ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $331,541 Small Business Innovation Research (SBIR) grant for the development of ReShape’s Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device, which utilizes its proprietary vagus nerve block (vBloc) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity. Specifically, the grant will fund the exploration of high-resolution endoscopic ultrasound (EUS) probes to aid accurate placement of the electrodes laparoscopically on the celiac and hepatic branches in large animals.
“ReShape’s DBSN™ device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose. Increased glycemic control, has been successfully demonstrated in a Zucker rat model of Type 2 diabetes as well as in an alloxan treated swine model of type 2 diabetes, both of which were completed with the help of an initial NIH grant,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences®. “We are currently exploring the device’s ability to treat hypoglycemia. We believe high-resolution EUS probes can be used to quickly and accurately locate the fine branches of the vagus nerve and aid in minimally invasive placements of DBSN™ electrodes and study off target effects during stimulation.”
“Awarding this third NIH SBIR grant brings the total received awards to $900,000, and is a testament to both our non-dilutive funding strategy and the NIH’s strong interest in the development of the novel DBSN™ device and its potential to address the significant, global diabetes market,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. “With the funding, to date, our team has successfully completed the pre-clinical development of the device, which utilizes bioelectronics to adjust insulin production and manage blood glucose to potentially treat Type 2 diabetes and hypoglycemia. It has also shown that this innovative technology may reduce diabetics’ dependence on medications in a very individualized manner with the goal of reducing costs of treatment and complications that arise from poorly controlled blood glucose and non-compliance with diabetes medications. The promise of the DBSN™ device is evidenced, not only by the volume of NIH funding, but also by the presentation of compelling preclinical evidence at multiple medical conferences. Backed by a strong intellectual property portfolio of 74 issued or pending patents related to vBloc, glucose control, AI and Bluetooth applications, we remain committed to furthering its development through similar NIH grants or potential strategic alliances.”
About Diabetes Bloc-Stim Neuromodulation™ Device
The Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system is a novel therapeutic concept that is implanted minimally invasively and delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The DBSN™ system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The DBSN™ system utilizes a proprietary, reversable and adjustable electrical blockade that we believe is key to the future of personalized medicine. We believe the DBSN™ system is superior to both standalone stimulation of the vagus nerve that has shown mixed results, and vagus nerve ligation that has undesirable effects.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.
For more information, please visit https://www.reshapelifesciences.com.
CONTACTS
ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
Link: https://www.streetinsider.com/dr/news.php?id=22160985
$RSLS >>> More DD
Usefulness of the ReShape intragastric balloon for obesity
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541059/
$RSLS >>> Patent issued last week!
ReShape Gastric Balloon
The Non-Surgical Weight Loss Procedure.
$RSLS >>> ReShape Lifesciences signs license agreement with Biorad Medisys for Obalon Gastric BalloonReShape Lifesciences signs license agreement with Biorad Medisys for Obalon Gastric Balloon
ReShape Lifesciences has signed an exclusive, royalty-bearing license agreement with Biorad Medysis (Biorad) to manufacture, commercialise and distribute the Obalon Gastric Balloon System in India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives.
Based in Mumbai, India, Biorad is an established, science-driven medical device manufacturer that has successfully manufactured and sold innovative medical devices in the urology, gastroenterology, orthopaedic and neurovascular industries, which is now expanding into the bariatric arena.
The license agreement provides $200,000 in upfront payments from Biorad to ReShape and ongoing license payments of 4% on
gross sales of the Obalon Balloon System in the territories. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.
“This exclusive agreement with Biorad represents the first step towards reintroducing our patented Obalon Balloon System technology to the global marketplace,” said Paul F Hickey, President and Chief Executive Officer of ReShape Lifesciences. “We believe that Biorad, with decades of experience manufacturing and distributing medical devices in the vast South Asia market, potentially reaching approximately 20% to 25% of the world’s population, is an ideal partner to expand the reach of ReShape’s Obalon technology. Our non-surgical, minimally invasive, Obalon System was the first swallowable, gas filled balloon system approved by the US Food and Drug Administration, around which we continue to build a strong intellectual property portfolio. We look forward to a fruitful partnership with Biorad, which we expect will lay the groundwork to catalyse the successful relaunch and joint commercialization of the balloon system in markets world-wide.”
Link: https://www.bariatricnews.net/post/reshape-lifesciences-signs-license-agreement-with-biorad-medisys-for-obalon-gastric-balloon
$RSLS >>> Proof of patent!
Systems and methods for determining failure of intragastric devices
Patent number: 11730619
Abstract: Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same are provided.
Type: Grant
Filed: March 23, 2021
Date of Patent: August 22, 2023
Assignee: RESHAPE LIFESCIENCES INC.
Inventors: Mark C. Brister, Neil R. Drake, Antonio C. Llevares, Sheldon Nelson, Daniel J Proctor, Andrew P. Rasdal, Keoni John Sundseth, Amy D.L. VandenBerg, Betty Wong
Link: https://patents.justia.com/patents-by-us-classification/606/192
$FOXO moving up & $RSLS about to explode imo. 2x FDA greenlight now.
$FOXO moving up & $RSLS about to explode imo. 2x FDA greenlight now!
Get size before lift-off, broski! ;)
$RSLS >>> ReShape Lifesciences Has Received FDA 510(k) Clearance For ReShape Calibration Tubes And Gastric Balloon Suction Catheter
https://www.sahmcapital.com/news/content/reshape-lifesciences-has-received-fda-510k-clearance-for-reshape-calibration-tubes-and-gastric-balloon-suction-catheter-2024-05-20
$RSLS >>> ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
https://finance.yahoo.com/news/reshape-lifesciences-receives-fda-pma-210500500.html
$FOXO go, also watch...
$RSLS! ;) (FDA go)
$RSLS from red to green. Took a starter here. Will add more ASAP.
Yes, bro. $250M merger about to hit the wires hard here. $FOXO
Good to see ya here, broski. GLTUA.
$FOXO @$.35 > ST_PT: $2+
Chart~ https://stockcharts.com/h-sc/ui?s=foxo&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411
$QH on close watch... breakout imminent!?
$LGND $LGNZZ $LGNDZ $LGNXZ $LGNYZ
On high watch. Setting up nicely.
DT is showing $13 cash per share... $TIRX
$TANH @.69 >>> Book Value: $34.84 per Share!!! $$$$$$$$
https://finviz.com/quote.ashx?t=TANH&ty=c&ta=1&p=w&r=y2
$TANH >>> EPS Y/Y TTM: +145.47%! $$$$$$$$
https://finviz.com/quote.ashx?t=TANH&ty=c&ta=1&p=w&r=y2